| Sign In to gain access to subscriptions and/or personal tools. |
Successful Management of Refractory Neonatal Seizures With MidazolamDivision of Pediatric Neurology, Department of Pediatrics, New York Presbyterian Hospital-Weill Cornell Medical College, New York
Division of Pediatric Neurology, Department of Pediatrics, New York Presbyterian Hospital-Weill Cornell Medical College, New York
Division of Pediatric Neurology, Department of Pediatrics, New York Presbyterian Hospital-Weill Cornell Medical College, New York, jal9012{at}nyp.org
Division of Pediatric Neurology, Department of Pediatrics, New York Presbyterian Hospital-Weill Cornell Medical College, New York
Division of Pediatric Neurology, Department of Pediatrics, New York Presbyterian Hospital-Weill Cornell Medical College, New York Seizures are indicative of underlying neurologic dysfunction in neonates. Repeated seizures may be deleterious to the brain even without disturbances of ventilation or perfusion. First-line antiepileptic drugs such as phenobarbital and phenytoin are not very effective in controlling seizures in neonates. Rapid control of status epilepticus with midazolam has been demonstrated in 2 previous studies with complete clinical and electrographic response in neonates who did not respond to phenobarbital and phenytoin. We report our experience with 3 neonates with status epilepticus. Seizures in all 3 neonates did not respond to phenobarbital and phenytoin but responded to midazolam infusion. Midazolam may be considered a safe and effective antiepileptic drug in refractory neonatal seizures of diverse etiologies.
Key Words: neonatal seizures midazolam
Journal of Child Neurology, Vol. 23, No. 6,
706-709 (2008) This article has been cited by other articles:
|
|
||||||||||||||


